|POZEN Names Dr. James Alexander Senior Vice President, Product Development|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 24, 2003--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company developing therapeutic advancements in a cost effective manner, announced today that W. James Alexander, M.D., M.P.H., F.A.C.P., has been named senior vice president, product development. In this role, Dr. Alexander is responsible for leading the company's product development activities, which include overseeing toxicology, pharmaceutics, clinical operations, biostatistics, data management, and regulatory affairs. He will report to John R. Plachetka, Pharm.D., chairman, president, and chief executive officer and will be a member of the executive committee.
"Jim's extensive experience in clinical development and regulatory affairs will be great assets as we move our product candidates through development and seek marketing approval," said Dr. Plachetka. "He has contributed to successful New Drug Applications in multiple therapeutic areas, including products for the treatment of migraine, epilepsy, asthma, bacterial infections, HIV, and other viral infections."
Dr. Alexander was previously president and chief medical officer at PharmaResearch Corporation with global responsibilities for medical and regulatory operations. Most recently, he was chief medical officer for Inveresk Research Group. Prior to joining PharmaResearch, he served as vice president and worldwide director for product safety and pharmacovigilance at GlaxoWellcome. During his career, Dr. Alexander has participated in the development of several leading medicines including Timentin(R), Famvir(R), Epivir(R), and Serevent(R).
Dr. Alexander received his M.D. from the University of Mississippi and his M.P.H. from the University of Alabama at Birmingham. He is board certified in internal medicine and infectious diseases.
POZEN is a pharmaceutical company developing therapeutic advancements in a cost effective manner. Product development efforts are focused on diseases with unmet medical needs where POZEN can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval of our product candidates, uncertainties in clinical trial results, resulting in, among other things, our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2003 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.